Welcome to our dedicated page for Integer Hldgs news (Ticker: ITGR), a resource for investors and traders seeking the latest updates and insights on Integer Hldgs stock.
Integer Holdings Corporation (NYSE: ITGR) is a medical device contract development and manufacturing organization (CDMO) that regularly issues news on its operations, financial performance, and corporate developments. The company focuses on serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets, and its updates reflect activity across these areas.
On this page, readers can follow ITGR news related to quarterly earnings, product line performance, and outlooks that Integer provides through press releases furnished with Form 8-K filings. These releases often include discussions of sales trends in Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets, along with non-GAAP financial measures such as adjusted operating income, adjusted EBITDA, adjusted net income, and adjusted earnings per share.
Integer’s news flow also covers strategic and governance events, such as leadership transitions, board appointments, and capital allocation decisions. Recent examples include the appointment of a new President and Chief Executive Officer, the election of a new director with extensive medical device industry experience, and the authorization of a share repurchase program by the Board of Directors.
In addition, Integer publishes updates on technology and market-facing activities, such as participation in medical society meetings and healthcare investor conferences. The company has highlighted innovations in neuromodulation and miniaturized active implantable medical devices, including high-performance batteries and integrated implantable pulse generator and lead systems, as well as its Xcellion Gen 3 fast charge lithium ion battery technology.
Investors and observers can use this news page to monitor how Integer communicates its strategy, product line dynamics, financing actions, and role as a CDMO in the cardiac rhythm management, neuromodulation, and cardio and vascular markets.
Integer (NYSE: ITGR) announced a planned board leadership transition. Independent Chair Pamela G. Bailey will not stand for re-election at the May 20, 2026 Annual Meeting. Following the meeting, the Board intends to appoint director Donald J. Spence as independent Chair.
Mr. Spence has served on the Board since 2016, chairs the Compensation & Organization Committee and sits on two other committees; Ms. Bailey thanked colleagues and endorsed the succession.
Integer (NYSE: ITGR) will webcast a conference call to discuss financial results and business highlights for the first quarter ended April 3, 2026. The call is scheduled for Thursday, April 30, 2026 at 8 a.m. CT (9 a.m. ET), following a news release of results earlier that day.
Dial-in numbers, Conference ID 3120125, webcast registration and an audio replay available for seven days will be provided via the company's Investor Relations website.
Integer (NYSE: ITGR) appointed James Flanagan and Aaron Kapito to its Board of Directors effective March 12, 2026, adding financial, governance and risk‑management expertise.
The appointments follow a cooperation agreement with Irenic Capital Management; two existing directors will not stand for re‑election at the annual meeting.
Integer (NYSE: ITGR) announced its executive leadership will participate in three investor conferences in March 2026: Raymond James (11:35 a.m. ET, March 3), Oppenheimer (12:40 p.m. ET, March 17) and KeyBanc (11:15 a.m. ET, March 18).
According to Integer, each event will be available via live webcast and replay under Investor Relations > News & Events at investor.integer.net.
Integer (NYSE:ITGR) reported fourth-quarter and full-year 2025 results on Feb 19, 2026, with 2025 sales of $1.854 billion (up 8%) and adjusted EPS of $6.40 (up 21%). Integer generated $196 million of operating cash flow, repurchased ~698,356 shares for $50 million, and ended 2025 with $1.185 billion total debt (leverage 3.0x).
The company maintained its 2026 outlook midpoint, targeting adjusted EPS $6.29–$6.78 and reiterated a plan to return to ~200 bps above-market organic sales growth by 2027.
Integer (NYSE: ITGR) will exhibit at MD&M West 2026 in Anaheim, Feb 3–5, unveiling an expanded 20 x 50 sq. ft. booth #3201 and showcasing R&D Velocity, an integrated R&D ecosystem linking design, prototyping and manufacturing to accelerate device manufacturability.
Integer will also highlight expanded medical coatings capabilities after recent acquisitions, plus cardiac rhythm, neuromodulation, and cardio/vascular product platforms.
Integer (NYSE: ITGR) will webcast a conference call to discuss fourth quarter and full year results for the period ended Dec. 31, 2025, on Thursday, Feb. 19, 2026 at 8 a.m. CT / 9 a.m. ET.
The company will issue a news release with financial results prior to the call. Domestic dial-in: (800) 715-9871; international dial-in: (646) 307-1963; conference ID: 3120125. Webcast registration is available via the Integer investor site and an audio replay will be available for seven days by dialing (800) 770-2030 or (609) 800-9909 using the same conference ID. Live and archived replay will be on Integer's Investor Relations website.
Integer (NYSE: ITGR) will exhibit at the North American Neuromodulation Society Annual Meeting in Las Vegas from Jan. 22–25, 2026. Visit booth #115 to see Integer’s work on neuromodulation and miniaturized active implantable medical devices (AIMDs) aimed at accelerating development timelines and reducing risk for device makers.
Integer will highlight full-system capabilities—from high-performance batteries to integrated implantable pulse generators and lead systems—and showcase the Xcellion® Gen 3 Fast Charge Lithium Ion battery, which offers best-in-class runtime and recharges in as little as 30 minutes.
Integer (NYSE: ITGR) said members of its executive leadership team will participate in two investor conferences in early December 2025.
Scheduled appearances: Piper Sandler 37th Annual Healthcare Conference at 8:00 a.m. ET on Tuesday, Dec. 2, 2025, and Citi 2025 Global Healthcare Conference at 9:45 a.m. ET on Wednesday, Dec. 3, 2025. Live webcasts and replays will be available under News & Events in the Investor Relations section at investor.integer.net.
Integer Holdings Corporation (NYSE: ITGR) announced on November 4, 2025 that its Board authorized a $200 million share repurchase program for the company's outstanding common stock. The company said it intends to primarily use cash on hand and free cash flows to fund repurchases. Management may execute repurchases opportunistically or under trading plans, and timing and volume will be at management's discretion. The Board and management characterized the program as reflecting confidence in Integer's strategy and financial position.